Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRS-343 in HER2-positive advanced solid tumors
NCT03330561Phase 1Completed
- Sponsor
- Pieris Pharmaceuticals
- Start
- Sep 2017
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Phase 1, open-label trial of cinrebafusp alfa in HER2-positive breast cancer, HER2-positive gastric cancer, HER2-positive bladder cancer and 1 more (2 arms), sponsored by Pieris Pharmaceuticals. Primary endpoint: Incidence and severity of Adverse Events at 36 months. Started Sep 2017; status: completed.
02
Drugs
cinrebafusp alfa
03
Conditions
HER2-positive breast cancerHER2-positive gastric cancerHER2-positive bladder cancerHER2-positive solid tumor (HER2+)
Beyond the preview
Go deeper on NCT03330561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03330561.